Arcturus: H1 2024 Rare Disease Drug Data On Deck

fatido/E+ via Getty Images Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is gearing up to report results from its phase 1b study using its inhaled messenger RNA [mRNA] treatment known as ARCT-032 for the treatment of patients with Cystic Fibrosis [CF]. There is an important catalyst to watch with respect to this program, which is that there will be the release of interim results from this phase 1b study in the 1st half of 2024. What makes this biotech unique is that its approach to treating this patient ...